Table 1

Baseline characteristics of included studies in the systematic review and meta-analysis

First author	MDA		Sample size (inter)	Mean (cont)	SD (cont)	Sample size (cont)	Dose of RSG (mg/day)	Duration (week)	Type of sample	Age (years)	Disease	M/F (inter)	M/F (cont)	MDA assay
First author	Mean (inter)	SD (inter)	Sample size (inter)	Mean (cont)	SD (cont)	Sample size (cont)	Dose of RSG (mg/day)	Duration (week)	Type of sample	Age (years)	Disease	M/F (inter)	M/F (cont)	MDA assay
Yilmaz15	0.004	0.002	25	0.007	0.003	25	4	12	Serum	23.92	PCOS	25F	25F	SPC
von Bibra13	0.006	0.0003	12	0.007	0.0007	12	8	16	Plasma	59	T2D	8/4	8/4	HPLC
Gupta31	0.0006	0.0001	30	0.0006	0.0001	30	8	12	Plasma	50	T2D	30F	30F	SPC
Lazich14	0.007	0.002	23	0.007	0.001	20	4	24	Serum	58.7	MS	9/14	14/6	ELISA
Atamer12	0.003	0.001	45	0.005	0.001	50	4	12	Serum	58.7	T2D	25/20	30/20	SPC
Huang16	14.3	8.9	40	11.2	4.1	40	4	12	Plasma	50.8	T2D	14/26	15/15	SPC
Li40	0.004	0.009	40	0.006	0.001	40	4	48	Plasma	40.36	T2D	21/19	21/19	SPC
Pasali41	0.001	0.0004	12	0.001	0.0003	12	8	24	Serum	53	T2D	6/6	6/6	SPC

Cont, control; F, Female; HPLC, high performance liquid chromatography; Inter, intervention; M, male; MDA, malondialdehyde; MS, metabolic syndrome; PCOS, polycystic ovary syndrome; RSG, rosiglitazone; SPC, spectrophotometry; T2D, type 2 diabetes.